| Not Yet Recruiting | DNV001 Injection in Patients With Hypercholesterolemia NCT07391722 | Hangzhou Dinovate Biotech Co., Ltd | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of NCT06889012 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monot NCT07444762 | Daewon Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282 NCT06747936 | Addpharma Inc. | Phase 3 |
| Recruiting | A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia NCT06568471 | Hasten Biopharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary NCT06386419 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C NCT06165250 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib NCT06314919 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administrati NCT06184269 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 NCT06475872 | Hanlim Pharm. Co., Ltd. | Phase 1 |
| Withdrawn | Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in NCT05798390 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Completed | A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertensi NCT05930028 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hyperchol NCT05657574 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Active Not Recruiting | Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD NCT05399992 | Novartis Pharmaceuticals | — |
| Completed | An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe NCT05559606 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholest NCT05118230 | Novartis Pharmaceuticals | — |
| Completed | A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A NCT05131997 | Addpharma Inc. | Phase 3 |
| Completed | Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage NCT04849000 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research NCT04844125 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia NCT05206578 | Ahn-Gook Pharmaceuticals Co.,Ltd | Phase 3 |
| Completed | Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 NCT06448962 | Addpharma Inc. | Phase 3 |
| Completed | Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholes NCT04643093 | Orient Pharma Co., Ltd. | Phase 3 |
| Unknown | To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients Wit NCT04659070 | Hanlim Pharm. Co., Ltd. | Phase 3 |
| Completed | Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia NCT04652349 | Hanmi Pharmaceutical Company Limited | Phase 3 |
| Completed | To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia NCT04584736 | JW Pharmaceutical | Phase 3 |
| Unknown | Effect of Probiotics on Lipid Management NCT03952169 | Sun Yat-sen University | N/A |
| Terminated | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participa NCT03433755 | Amgen | Phase 3 |
| Completed | Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia NCT03413462 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 3 |
| Unknown | Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholester NCT03464682 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 3 |
| Completed | Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male NCT02941848 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting NCT03516955 | Hikma Pharmaceuticals LLC | — |
| Completed | Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia NCT03571087 | Hanlim Pharm. Co., Ltd. | Phase 3 |
| Completed | Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia NCT02445352 | Alvogen Korea | Phase 3 |
| Completed | Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia NCT02205606 | Hanmi Pharmaceutical Company Limited | Phase 3 |
| Completed | A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Prim NCT02087917 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 2 |
| Unknown | Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia NCT02009787 | Shi Yang | N/A |
| Completed | Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a P NCT01879319 | Amgen | Phase 3 |
| Completed | Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen NCT01849497 | Amgen | Phase 3 |
| Terminated | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hyperchol NCT01335997 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy NCT01274559 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants NCT01294683 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia NCT00746811 | Provident Clinical Research | Phase 4 |
| Completed | A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combi NCT01012219 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia NCT00941603 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercho NCT00867165 | Organon and Co | Phase 3 |
| Completed | Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in J NCT00871351 | Organon and Co | Phase 4 |
| Completed | Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment NCT00724477 | Organon and Co | — |
| Completed | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) NCT00479388 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | MK-0524B Lipid Study (MK-0524B-063) NCT00479882 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety NCT00776321 | Karo Bio AB | Phase 2 |
| Completed | Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hype NCT00704535 | Organon and Co | — |
| Completed | Lipid Efficacy Study (0524B-022)(COMPLETED) NCT00269217 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels NCT00249249 | Kowa Research Europe | Phase 3 |
| Completed | A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hype NCT03882905 | Organon and Co | Phase 3 |